In the News

PULMONX ANNOUNCES NATIONAL REIMBURSEMENT IN FRANCE FOR ZEPHYR ENDOBRONCHIAL VALVES, A REVOLUTIONARY TREATMENT OPTION FOR PATIENTS WITH SEVERE EMPHYSEMA/COPD

Pulmonx Corporation announced today that the French Health Ministry has granted national reimbursement for the Zephyr Endobronchial Valve, the first minimally-invasive treatment option for patients with severe emphysema, a form of Chronic Obstructive Pulmonary Disease (COPD).

Read More


A NEW REPORT CONFIRMS SIGNIFICANT BENEFITS IN PATIENT REPORTED OUTCOMES AT ONE YEAR FOLLOWING THE NON-SURGICAL ZEPHYR VALVE PROCEDURE FOR COPD/EMPHYSEMA

Pulmonx Corporation announced today that the French Health Ministry has granted national reimbursement for the Zephyr Endobronchial Valve, the first minimally-invasive treatment option for patients with severe emphysema, a form of Chronic Obstructive Pulmonary Disease (COPD).

Read More


PULMONX SECURES $66M IN FINANCING TO SUPPORT COMMERCIAL ACCELERATION OF THE ZEPHYR VALVE SYSTEM, A MINIMALLY-INVASIVE TREATMENT FOR SEVERE EMPHYSEMA

Pulmonx Corporation, a commercial-stage medical technology company that provides a minimally-invasive treatment for patients with severe emphysema, announces a $66 million financing led by Ally Bridge Group, a leading global life science investor.

Read More


PULMONX NAMES INDUSTRY VETERAN TO BOARD OF DIRECTORS

Pulmonx Corporation, a commercial-stage medical technology company that provides a minimally invasive treatment for patients
with severe emphysema, today announced that Daniel Florin has joined its Board of Directors.

Read More


PULMONX ANNOUNCES THAT UNITEDHEALTHCARE, THE LARGEST COMMERCIAL INSURER IN THE UNITED STATES, HAS LIFTED COVERAGE RESTRICTIONS ON THE ZEPHYR VALVE, A MINIMALLY-INVASIVE TREATMENT OPTION FOR SEVERE EMPHYSEMA (COPD)

Pulmonx Corporation, a leader in therapeutic pulmonary device technologies, announced today that UnitedHealthcare®, the largest commercial insurer in the United States, has lifted coverage restrictions on endobronchial valves, a minimally-invasive treatment option for severe emphysema, a form of COPD.

Read More


THE NEW 2020 REPORT FROM THE GLOBAL INITIATIVE FOR CHRONIC OBSTRUCTIVE LUNG DISEASE (GOLD) GIVES HIGHEST EVIDENCE RATING TO ENDOBRONCHIAL VALVES, INCLUDING THE ZEPHYR VALVE, FOR TREATMENT OF EMPHYSEMA / COPD

Global Initiative for Chronic Obstructive Disease (GOLD) has upgraded the evidence level rating for bronchoscopic lung volume reduction (BLVR) with endobronchial valves, including the Zephyr Valve, for the treatment of emphysema / chronic obstructive pulmonary disease (COPD).

Read More


PULMONX ANNOUNCES THAT PRIORITY HEALTH NOW COVERS THE ZEPHYR VALVE, A LESS INVASIVE TREATMENT OPTION FOR SEVERE EMPHYSEMA (COPD)

Pulmonx Corporation, a leader in diagnostic and therapeutic pulmonary device technologies, announced today that its Zephyr® Valve has received positive coverage from Humana® under its new endobronchial valve (EBV) coverage policy.

Read More


PULMONX CLOSES $65 MILLION FINANCING AND ADDS CHIEF FINANCIAL OFFICER

Pulmonx Corporation, a leader in diagnostic and therapeutic pulmonary device technologies, announced today that its Zephyr® Valve has received positive coverage from Humana® under its new endobronchial valve (EBV) coverage policy.

Read More


PULMONX ANNOUNCES THAT HUMANA HAS ISSUED A POSITIVE COVERAGE POLICY FOR THE ZEPHYR VALVE, A LESS INVASIVE TREATMENT OPTION FOR SEVERE EMPHYSEMA (COPD)

Pulmonx Corporation, a leader in diagnostic and therapeutic pulmonary device technologies, announced today that its Zephyr® Valve has received positive coverage from Humana® under its new endobronchial valve (EBV) coverage policy.

Read More


NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE (NICE) ISSUES NEW GUIDELINES FOR COPD, RECOMMENDING SEVERE PATIENTS BE EVALUATED FOR BRONCHOSCOPIC LUNG VOLUME REDUCTION

The US Food and Drug Administration (FDA) has approved the Zephyr® Endobronchial Valve System for treating severe emphysema patients.

Read More


PULMONX ANNOUNCES THAT ONE OF THE LEADING HEALTH CARE PROVIDERS IN THE UNITED STATES NOW COVERS THE ZEPHYR VALVE FOR BRONCHSCOPIC LUNG VOLUME REDUCTION IN PATIENTS WITH SEVERE EMPHYSEMA

The US Food and Drug Administration (FDA) has approved the Zephyr® Endobronchial Valve System for treating severe emphysema patients.

Read More


FDA APPROVES ZEPHYR ENDOBRONCHIAL VALVE FOR TREATING SEVERE EMPHYSEMA

The US Food and Drug Administration (FDA) has approved the Zephyr® Endobronchial Valve System for treating severe emphysema patients.

Read More